BridgeBio Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
BBIO$77.93+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
As of December 31, 2023, the following are the material properties that we occupy:
| PropertyDescription | Location | SquareFootage | Owned orLeased | InitialLeaseTerm EndDate | Lease ExtensionOptions |
|---|---|---|---|---|---|
| Office space and laboratory facility | Raleigh, NC | 17,631 | Leased | 2024 | Option to extend of up to five-years |
| Office space and laboratory facility | Palo Alto, CA | 9,789 | Leased | 2024 | One-year option to extend |
| Office space | San Francisco, CA | 52,604 | Leased | 2026 | Two-year option to extend |
| Laboratory facility | Montreal, Québec | 20,039 | Leased | 2033 | Five-year option to extend |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.